The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1431
December 9, 2013
View Complete Issue         Table of Contents 2019 
Ferric Carboxymaltose (Injectafer) for Iron Deficiency Anemia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Ferric Carboxymaltose (Injectafer) for Iron Deficiency Anemia
December 9, 2013 (Issue: 1431)
The FDA has approved ferric carboxymaltose (Injectafer – American Regent), a 2-dose intravenous iron replacement product, for treatment of iron deficiency anemia (IDA) in adults who cannot tolerate or have had an unsatisfactory response to oral...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Ferric Carboxymaltose (Injectafer) for Iron Deficiency Anemia
Article code: 1431d
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.